Employing a definitive test to detect substances whose interactions may cause adverse drug events can enhance a provider’s insights, drive clinical...
InterACT Rx™ identified at least one drug-drug interaction (DDI) between recently ingested substances in as many as 20% of patients. Nashville,...
AcuRiseID™ is a new urinalysis that monitors medication adherence in people with mental illness and substance abuse disorder Nashville, Tennessee (Sept....
Aegis Sciences director honored for career achievements Nashville, Tenn. (August 3, 2018) – Kara Allen, Aegis Sciences Corporation’s Director, Recruitment and University...
Nashville, TN – July 24, 2018 - Aegis Sciences Corporation, a national leader in healthcare and forensic laboratory sciences, is expanding! Wednesday,...
InterACT RxTM testing detects over 120 substances known to cause adverse drug interactions. Nashville, Tenn. (July 12, 2018) – Aegis Sciences Corporation, a...
Sign up for the Aegis Newsletter